{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:45:55Z","timestamp":1772664355677,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04099"],"award-info":[{"award-number":["17H04099"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40261-022-01168-0","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:03:28Z","timestamp":1654686208000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan"],"prefix":"10.1007","volume":"42","author":[{"given":"Xiuting","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-597X","authenticated-orcid":false,"given":"Kensuke","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"7","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, et al. Updated trends in cancer in Japan: incidence in 1985\u20132015 and mortality in 1958\u20132018\u2014a sign of decrease in cancer incidence. J Epidemiol. 2021;31(7):426\u201350.","journal-title":"J Epidemiol"},{"key":"1168_CR2","unstructured":"National Cancer Center. Cancer Statistics in Japan (Japanese). https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html#a7. Accessed 10 Oct 2021."},{"key":"1168_CR3","unstructured":"Institute of Medical Information Science. Medical Disease: An illustrated Reference Guide vol. 4\u2014Respiratory System 3rd Edition. Tokyo: Medic Media; 2018."},{"key":"1168_CR4","unstructured":"Japan Ministry of Health Labour and Welfare. Overview of national medical expenses 1995\u20132018 (Japanese). https:\/\/www.mhlw.go.jp\/toukei\/list\/37-21c.html. Accessed 10 Oct 2021."},{"key":"1168_CR5","unstructured":"Japan Ministry of Health Labour and Welfare. Overview of national medical expenses in 2018 (Japanese). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/k-iryohi\/18\/dl\/data.pdf. Accessed 10 Oct 2021."},{"key":"1168_CR6","unstructured":"Statistics of Japan. National Healthcare fee (Japanese). https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&cycle=8&toukei=00450032&tstat=000001020931&tclass1=000001045985&tclass2val=0&stat_infid=000012450135. Accessed 10 Oct 2021."},{"key":"1168_CR7","unstructured":"The Japan Lung Cancer Society. Guidelines for the Treatment of Lung Cancer, 2020 Edition (Japanese). https:\/\/www.haigan.gr.jp\/guideline\/2020\/1\/2\/200102070100.html. Accessed 10 Oct 2021."},{"issue":"21","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022;17(2):289\u2013308.","journal-title":"J Thorac Oncol"},{"key":"1168_CR10","unstructured":"Japan Ministry of Health Labour and Welfare. Minutes of the Second Subcommittee on Medicinal Products for Human Use, Pharmaceutical Affairs and Food Sanitation Council, October 30, 2020 (Japanese). https:\/\/www.mhlw.go.jp\/stf\/newpage_16467.html. Accessed 19 Jan 2022."},{"key":"1168_CR11","unstructured":"National Institute for Health and Care Excellence. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer Technology appraisal guidance. 2021 https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10472. Accessed 10 Oct 2021."},{"key":"1168_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.580459","volume":"12","author":"X Wan","year":"2021","unstructured":"Wan X, Zeng X, Peng L, Peng Y, Liu Q, Yi L, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small-cell lung cancer. Front Pharmacol. 2021;12: 580459.","journal-title":"Front Pharmacol"},{"key":"1168_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.573852","volume":"12","author":"X Hao","year":"2021","unstructured":"Hao X, Shen A, Wu B. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced non-small-cell lung cancer. Front Pharmacol. 2021;12: 573852.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1168_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8787","volume":"4","author":"PT Courtney","year":"2021","unstructured":"Courtney PT, Yip AT, Cherry DR, Salans MA, Kumar A, Murphy JD. Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer. JAMA Netw Open. 2021;4(5): e218787.","journal-title":"JAMA Netw Open"},{"issue":"14","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2217\/imt-2020-0112","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Zhang T, Xu Y, Lu P, Zhu J, Liang W, et al. Cost\u2013effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. Immunotherapy. 2020;12(14):1067\u201375.","journal-title":"Immunotherapy"},{"key":"1168_CR16","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3389\/fonc.2020.01649","volume":"10","author":"H Hu","year":"2020","unstructured":"Hu H, She L, Liao M, Shi Y, Yao L, Ding D, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer. Front Oncol. 2020;10:1649.","journal-title":"Front Oncol"},{"issue":"1","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351.","journal-title":"Value Health"},{"issue":"8","key":"1168_CR18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.healthpol.2017.06.001","volume":"121","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T. New decision-making processes for the pricing of health technologies in Japan: the FY 2016\/2017 pilot phase for the introduction of economic evaluations. Health Policy. 2017;121(8):836\u201341.","journal-title":"Health Policy"},{"issue":"3","key":"1168_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/S0266462320000264","volume":"36","author":"T Shiroiwa","year":"2020","unstructured":"Shiroiwa T. Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan. Int J Technol Assess Health Care. 2020;36(3):270\u20136.","journal-title":"Int J Technol Assess Health Care"},{"key":"1168_CR20","unstructured":"Ono Pharmaceutical Industry Co. & Bristol-Myers Squibb Co. Trends in Opdivo (Japanese). 2021 https:\/\/www.ono.co.jp\/sites\/default\/files\/ja\/ir\/library\/financial_results\/presen\/20210730_3.pdf. Accessed 19 Jan 2022."},{"key":"1168_CR21","unstructured":"NICE Decision Support Unit. NICE DSU TECHNICAL SUPPORT DOCUMENT 19: Partitioned survival analysis for decision modelling in health care: a critical review. 2017 http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf. Accessed 19 Jan 2022."},{"key":"1168_CR22","unstructured":"Ankit Rohatgi. WebPlotDigitizer Version: 4.5. https:\/\/automeris.io\/WebPlotDigitizer. Accessed 10 October 2021."},{"issue":"1","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12(1):1\u201313.","journal-title":"BMC Med Res Methodol"},{"key":"1168_CR24","unstructured":"National Cancer Center. Aggregate survival rate of hospital cancer registries (Japanese). https:\/\/ganjoho.jp\/reg_stat\/statistics\/brochure\/hosp_c_reg_surv.html. Accessed 10 Oct 2021."},{"key":"1168_CR25","unstructured":"Global Health Consulting. 3-year cancer survival rates published for the first time, with characteristics of 3-year, 5-year, and 10-year survival rates depending on stage and location\u2014National Cancer Center (Japanese). 2018 https:\/\/gemmed.ghc-j.com\/?p=22470. Accessed 10 Oct 2021."},{"key":"1168_CR26","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health Labour and Welfare (MHLW). Full Scale Introduction of Cost-Effectiveness Evaluations in Japan. 2019 https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf. Accessed 10 Oct 2021."},{"issue":"3","key":"1168_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health. 2017;20(3):372\u20138.","journal-title":"Value Health"},{"key":"1168_CR28","unstructured":"Ono Pharmaceutical Industry Co. & Bristol-Myers Squibb Co. Guide for the proper use of Opdivo and Yervoy (Japanese). https:\/\/www.opdivo.jp\/file-download\/download\/private\/6211. Accessed 10 Oct 2021."},{"key":"1168_CR29","unstructured":"Statistics of Japan. National Health and Nutrition Survey (Japanese). 2018 https:\/\/www.e-stat.go.jp\/dbview?sid=0003224177. Accessed 10 Oct 2021."},{"key":"1168_CR30","unstructured":"Institute of Medical Information. List of drug effects and drug prices for receipt clerks (Japanese): Jiho Inc; 2021."},{"key":"1168_CR31","unstructured":"Kakaku.com insurance Inc. Hospitalization Costs Simulation (Japanese). https:\/\/hoken.kakaku.com\/hospi-rate\/. Accessed 10 Oct 2021."},{"key":"1168_CR32","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health Labour and Welfare (MHLW). Survey of Actual medical benefits (2016) (Japanese). https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&toukei=00450389&tstat=000001044924&cycle=0&tclass1=000001044945&tclass2=000001117178&tclass3val=0. Accessed 10 Oct 2021."},{"key":"1168_CR33","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health Labour and Welfare (MHLW). Patient Survey (2017) (Japanese). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/17\/index.html. Accessed 10 Oct 2021."},{"issue":"1","key":"1168_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100394","volume":"7","author":"KJ O'Byrne","year":"2022","unstructured":"O\u2019Byrne KJ, Lee KH, Kim SW, Park K, Nishio M, Sakai H, et al. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open. 2022;7(1): 100394.","journal-title":"ESMO Open"},{"issue":"12","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares MJ. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613\u201321.","journal-title":"Value Health"},{"issue":"3","key":"1168_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jval.2018.10.007","volume":"22","author":"A Bullement","year":"2019","unstructured":"Bullement A, Latimer NR, Bell GH. Survival extrapolation in cancer immunotherapy: a validation-based case study. Value Health. 2019;22(3):276\u201383.","journal-title":"Value Health"},{"issue":"22","key":"1168_CR37","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"33","key":"1168_CR38","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J Clin Oncol. 2020;38(33):3863\u201373.","journal-title":"J Clin Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01168-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T10:18:30Z","timestamp":1656757110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01168-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"15 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) Grant number 17H04099 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT)\/Japan Society for the Promotion of Science (JSPS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Some of the data generated during and\/or analyzed during the current study are not publicly available but are available from the corresponding author on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The model file created by TreeAge Pro is not publicly available but is available from the corresponding author on request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study design: XM and KeM. Data collection: XM, KeM, and KoM. Data analysis: XM, KeM, and KoM. Data interpretation: XM, KeM, KoM, and KS. Manuscript drafting: XM, and KeM. Manuscript content revision: XM and KeM. Final manuscript version approval: XM, KeM, KoM, and KS. KeM takes responsibility for the integrity of the data analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}